Biodexa (NASDAQ:BDRX) stock shot up 70% in morning trading Thursday after the company re-released positive data from a Phase 2 study for its drug eRapa in the treatment of Familial Adenomatous ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous ...

Biodexa Pharmaceuticals shares surge following phase 2 trial results for eRapa, a potential treatment for Familial Adenomatous Polyposis. The study showed a 17% median reduction in polyp burden ...

Among patients who received eRapa 0.5mg daily every other week (cohort 2), 89% were deemed non-progressors, with a median decrease in polyp burden of 29% at 12 months.

April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis ...

An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum. FAP is a substantially genetic orphan ...

In summary, eRapa appeared safe and well-tolerated with a significant 24% reduction in the total polyp burden at six months compared with baseline (p=0.04) and an overall 83% non-progression rate.

May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation foll. Tuesday, 02 January 2024 12:17 GMT. عربي. Log in. Remember Me ...

March 6, 2025. Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP. Biodexa is finalizing plans to initiate an international ...

CARDIFF, UK - Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a biopharmaceutical company, has reported positive results from a Phase 2 clinical trial for eRapa, its investigational drug for Familial ...

Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), ...

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous ...